Non- or reduced glistenings intraocular lens and method of manufacturing same

• US 20070282057A1
• Filed: 05/21/2007
• Published: 12/06/2007
• Est. Priority Date: 06/01/2006
• Status: Active Grant

• Current Assignee: Advanced Vision Science, Inc. (Santen Pharmaceutical Company Limited)
• Original Assignee: Advanced Vision Science, Inc. (Santen Pharmaceutical Company Limited)
• Inventors: Mentak, Khalid, Aldred, Margaret
• Granted Patent: US 7,789,509 B2
• Time in Patent Office: Days
• US Class Current: 524/556
• CPC Class Codes: A61F 2/16 Intraocular lenses
• CPC Class Codes: A61F 2002/1699 Additional features not otherwise provided for
• CPC Class Codes: A61F 9/00 Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand caps with means for protecting the eyes A42B1/018; visors for helmets A42B3/22; retractors A61B17/02; manipulators specially adapted for use in surgery A61B34/70; appliances to aid invalids to move about A61H3/00; exercisers for the eyes A61H5/00; eye baths A61H35/02; sunglasses or goggles having the same features as spectacles G02C
• CPC Class Codes: B29D 11/00 Producing optical elements, e.g. lenses or prisms grinding or polishing of optical elements B24B; constructional form of optical elements G02B; optical parts of spectacles G02C7/00
• CPC Class Codes: B29D 11/00009 Production of simple or compound lenses
• CPC Class Codes: B29D 11/023 Implants for natural eyes

Abstract

The present invention relates to an intraocular lens which exhibits reduced or eliminated glistenings when implanted into the eye of a patient in need thereof and to a method of preparing such lens.

Claims

1. An intraocular lens, comprising:

an optical polymer or polymer blend having an equilibrium water content of from about 1 wt % to about 12 wt %; and

,

sufficient isotonic saline to bring the polymer or polymer blend once it has been formed into a lens to its equilibrium water content at a temperature at or above at or above approximately 37°

C.

2. The intraocular lens of claim 1, wherein the lens is a foldable intraocular lens.

3. The intraocular lens of claim 1, wherein the equilibrium water content of the polymer or polymer blend is from about 2 wt % to about 8 wt %.

4. The intraocular lens of claim 1, wherein the equilibrium water content of the polymer or polymer blend is from about 3 wt % to about 6 wt %.

5. The intraocular lens of claim 1, wherein the optical polymer or polymer blend is a copolymer of poly(ethylene glycol)phenyl ether acrylate, styrene, 2-hydroxyethyl methacrylate and ethylene glycol dimethacrylate.

6. The intraocular lens of claim 5, wherein the copolymer comprises about 40 wt % poly(ethylene glycol)phenyl ether acrylate, about 26 wt % styrene, about 30 wt % 2-hydroxyethyl methacrylate and about 4 wt % ethylene glycol dimethylacrylate.

7. The intraocular lens of claim 1, wherein the isotonic saline is selected from the group consisting of balanced salt solution, blood bank saline and phosphate buffered saline.

8. A method of reducing or eliminating glistenings in an intraocular lens, comprising:

providing an intraocular lens comprising a polymer or polymer blend having an equilibrium water content of from about 1 wt % to about 12 wt % at about 37°

C.;

contacting the intraocular lens with isotonic saline solution at a temperature of about 20°

C. to about 90°

C. for from about 1 hour to about 36 hours;

sterilizing the intraocular lens while maintaining it at its equilibrium water content; and

,

implanting the intraocular lens into the eye of a patient in need thereof or storing the intraocular lens in sterile isotonic saline until needed for implantation into the eye of a patient in need thereof.

9. The method of claim 8, wherein the temperature of the isotonic saline solution is from about 30°

C. to about 80°

C. and the contact time is from about 4 hours to about 30 hours.

10. The method of claim 8, wherein the temperature of the isotonic saline solution is from about 40°

C. to about 70°

C. and the contact time is from about 5 hours to about 24 hours.

11. The method of claim 8, wherein the intraocular lens is foldable.

12. The method of claim 8, wherein the intraocular lens is contacted with the isotonic saline solution during manufacture subsequent to solvent extraction and prior to sterilization.

13. The method of claim 8, wherein the intraocular lens is contacted with the isotonic saline solution subsequent to sterilization, either during manufacture or after manufacture using sterile isotonic saline solution.

14. The method of claim 13, wherein when the lens is contacted with isotonic saline after manufacture, it has been dried prior to contact with the isotonic saline solution.

15. The method of claim 8, wherein the intraocular lens has been commercially packaged prior to contact with the isotonic saline solution.

16. The method of claim 8, wherein the equilibrium water content of the polymer or blend of polymers is from about 2 wt % to about 8 wt % at about 37°

C.

17. The method of claim 8, wherein the equilibrium water content of the polymer or blend of polymers is from about 3 wt % to about 6 wt % at about 37°

C.

18. The method of claim 8, wherein the polymer or polymer blend comprises a copolymer comprising poly(ethylene glycol)phenyl ether acrylate, styrene, 2-hydroxyethyl methacrylate and ethylene glycol dimethacrylate.

19. The method of claim 18, wherein the copolymer comprises about 40 wt % poly(ethylene glycol)phenyl ether acrylate, about 26 wt % styrene, about 30 wt % 2-hydroxyethyl methacrylate and about 4 wt % ethylene glycol dimethylacrylate.

20. The method of claim 8, wherein the isotonic saline is selected from the group consisting of balanced salt solution, blood bank saline and phosphate buffered saline.